Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care.

Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, Vishnu P, Bodepudi S, Shareef Z, Ahmed S, Jani P, Paulus A, Grover A, Alegria VR, Ailawadhi M, Chanan-Khan A, Ailawadhi S.

JCO Oncol Pract. 2020 Jan 21:JOP1900309. doi: 10.1200/JOP.19.00309. [Epub ahead of print]

PMID:
32048939
2.

Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies.

Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V.

JCO Oncol Pract. 2020 Feb;16(2):56-66. doi: 10.1200/JOP.19.00335.

PMID:
32045556
3.

Familial Success in Allergen Desensitization.

Rowane M, Shilian R, Jhaveri DK, Tcheurekdjian HH, Sher TH, Hostoffer R Jr.

Allergy Rhinol (Providence). 2019 Nov 19;10:2152656719890315. doi: 10.1177/2152656719890315. eCollection 2019 Jan-Dec.

4.

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma.

Parrondo RD, Sher T.

Onco Targets Ther. 2019 Oct 14;12:8467-8478. doi: 10.2147/OTT.S192490. eCollection 2019.

5.

Corrigendum to 'Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis' [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700].

Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2020 Jan;26(1):209-212. doi: 10.1016/j.bbmt.2019.09.014. Epub 2019 Oct 11. No abstract available.

PMID:
31610149
6.

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.

Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M.

Blood Cancer J. 2019 Sep 30;9(10):75. doi: 10.1038/s41408-019-0237-1.

7.

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis.

Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2020 Jan;26(1):76-82. doi: 10.1016/j.bbmt.2019.08.019. Epub 2019 Sep 5.

PMID:
31494227
8.

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R.

Anticancer Drugs. 2019 Sep;30(8):859-865. doi: 10.1097/CAD.0000000000000810.

PMID:
31415286
9.

Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities.

Ailawadhi S, Azzouqa AG, Hodge D, Cochuyt J, Jani P, Ahmed S, Sher T, Roy V, Ailawadhi M, Alegria VR, Manochakian R, Vishnu P, Grover A, Abdulazeez MF, Paulus A, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):619-623. doi: 10.1016/j.clml.2019.06.010. Epub 2019 Jun 26.

PMID:
31377212
10.

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis.

Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1695-1700. doi: 10.1016/j.bbmt.2019.05.027. Epub 2019 May 25. Erratum in: Biol Blood Marrow Transplant. 2020 Jan;26(1):209-212.

PMID:
31132453
11.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2020 Jan 31;105(2):348-357. doi: 10.3324/haematol.2019.219626. Print 2020.

12.

Intraocular involvement of Mantle cell lymphoma: A case report and literature review.

Iqbal M, Castano YG, Sher T, Kharfan-Dabaja MA.

Hematol Oncol Stem Cell Ther. 2019 Apr 6. pii: S1658-3876(19)30027-5. doi: 10.1016/j.hemonc.2019.03.002. [Epub ahead of print]

13.

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.

Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A.

Clin Cancer Res. 2019 Jul 1;25(13):3974-3985. doi: 10.1158/1078-0432.CCR-18-3412. Epub 2019 Apr 2.

14.

First Report of Hereditary Lysozyme Amyloidosis in a South Asian Family.

Iqbal M, Jani P, Ahmed S, Sher T.

Case Rep Hematol. 2019 Feb 10;2019:5092496. doi: 10.1155/2019/5092496. eCollection 2019.

15.

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34. doi: 10.1016/j.clml.2018.08.018. Epub 2018 Sep 5.

PMID:
30340993
16.

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T.

Br J Haematol. 2018 Oct;183(2):196-211. doi: 10.1111/bjh.15515. Epub 2018 Aug 6.

PMID:
30080238
17.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9. Review.

18.

Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.

Ailawadhi S, Dholaria BR, Khurana S, Sher T, Alegria V, Paulus A, Ailawadhi M, Mehta A, Chanan-Khan A, Roy V.

Br J Haematol. 2019 Apr;185(2):347-350. doi: 10.1111/bjh.15458. Epub 2018 Jul 5. No abstract available.

PMID:
29978498
19.

Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma.

Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, Spaulding A, Sher T, Ailawadhi M, Bhatia K, Ahmed S, Tan W, Chanan-Khan A, Ailawadhi S.

Blood Adv. 2018 May 22;2(10):1120-1128. doi: 10.1182/bloodadvances.2018016717.

20.

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM.

Blood. 2018 Jul 19;132(3):293-306. doi: 10.1182/blood-2017-10-812701. Epub 2018 Apr 25.

21.

Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience.

Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H.

Leuk Lymphoma. 2018 Nov;59(11):2727-2730. doi: 10.1080/10428194.2018.1452220. Epub 2018 Mar 23. No abstract available.

PMID:
29566563
22.

Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.

Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A.

Cancer. 2018 Apr 15;124(8):1710-1721. doi: 10.1002/cncr.31237. Epub 2018 Jan 23.

23.

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ.

Leukemia. 2018 Mar;32(3):719-728. doi: 10.1038/leu.2017.258. Epub 2017 Sep 1.

PMID:
28860655
24.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.

Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ.

Blood. 2017 Sep 7;130(10):1198-1204. doi: 10.1182/blood-2017-05-782961. Epub 2017 Jul 6.

25.

Stem cell transplantation for immunoglobulin light chain amyloidosis.

Sher T, Gertz MA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):129-137. doi: 10.1016/j.currproblcancer.2017.03.001. Epub 2017 Mar 16. Review.

PMID:
28457657
26.

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA.

Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11. Review.

27.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB.

JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. Review.

28.

Post-Transplant Lymphoproliferative Disorder Presenting as CD20-Negative Plasmablastic Lymphoma in the Lung.

Kaleem T, Crozier JA, Menke DM, Sher T.

Rare Tumors. 2016 Sep 5;8(3):6220. eCollection 2016 Sep 5.

29.

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

Sher T, Fenton B, Akhtar A, Gertz MA.

Blood. 2016 Oct 13;128(15):1987-1989. Epub 2016 Aug 19. No abstract available.

PMID:
27543437
30.

Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA.

Nat Genet. 2016 Jan;48(1):101. doi: 10.1038/ng0116-101b. No abstract available.

PMID:
26711112
31.

Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

Sher T, Dispenzieri A, Gertz MA.

Biol Blood Marrow Transplant. 2016 May;22(5):796-801. doi: 10.1016/j.bbmt.2015.10.010. Epub 2015 Oct 22. Review.

32.

Antibody based immunotherapy for multiple myeloma: it's about time.

Sher T, Gertz MA.

Leuk Lymphoma. 2016 Feb;57(2):269-275. doi: 10.3109/10428194.2015.1092530. Epub 2015 Dec 16.

PMID:
26373636
33.

Delayed Anaphylaxis to the flu vaccine unrelated to known non-viral components.

David J, Horbal J, Tcheurekdjian H, Sher TH, Hostoffer R.

Eur Ann Allergy Clin Immunol. 2015 Sep;47(5):159-60.

34.

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA.

Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009. Review.

PMID:
26250727
35.

Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review.

Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S.

Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):578-85. doi: 10.1016/j.clml.2015.06.005. Epub 2015 Jun 19.

PMID:
26198444
36.

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.

Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A.

Br J Haematol. 2015 May;169(3):377-90. doi: 10.1111/bjh.13304. Epub 2015 Feb 17.

37.

Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type.

Swaika A, Menke DM, Jain MK, Sher T.

Ann Hematol. 2015 May;94(5):895-6. doi: 10.1007/s00277-014-2253-3. Epub 2014 Nov 15. No abstract available.

PMID:
25394720
38.

Pathophysiology and treatment of cardiac amyloidosis.

Gertz MA, Dispenzieri A, Sher T.

Nat Rev Cardiol. 2015 Feb;12(2):91-102. doi: 10.1038/nrcardio.2014.165. Epub 2014 Oct 14. Review.

PMID:
25311231
39.

First report of Nocardia beijingensis infection in an immunocompetent host in the United States.

Crozier JA, Andhavarapu S, Brumble LM, Sher T.

J Clin Microbiol. 2014 Jul;52(7):2730-2. doi: 10.1128/JCM.00588-14. Epub 2014 May 14.

40.

Mantle cell lymphoma and diffuse large B-cell lymphoma of the testis: a unique case of composite non-Hodgkin lymphoma.

Andhavarapu S, Crozier JA, Jiang L, Sher T.

Eur J Haematol. 2014 Dec;93(6):537-42. doi: 10.1111/ejh.12344. Epub 2014 May 22.

PMID:
24750331
41.

Partners empowered: a couple-based intervention for newly diagnosed cancer.

McMahon ME, Gremore TM, Cella D, Sher TG.

Psychooncology. 2014 Jul;23(7):832-4. doi: 10.1002/pon.3490. Epub 2014 Feb 4. No abstract available.

PMID:
24497302
42.

The partners for life program: a couples approach to cardiac risk reduction.

Sher T, Braun L, Domas A, Bellg A, Baucom DH, Houle TT.

Fam Process. 2014 Mar;53(1):131-49. doi: 10.1111/famp.12061. Epub 2014 Feb 5.

43.

The rational patient and beyond: implications for treatment adherence in people with psychiatric disabilities.

Corrigan PW, Rüsch N, Ben-Zeev D, Sher T.

Rehabil Psychol. 2014 Feb;59(1):85-98. doi: 10.1037/a0034935. Epub 2014 Jan 20. Review.

44.

Recent advances in the diagnosis and management of cardiac amyloidosis.

Sher T, Gertz MA.

Future Cardiol. 2014 Jan;10(1):131-46. doi: 10.2217/fca.13.85. Review.

PMID:
24344669
45.

Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells.

Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2014 Mar;55(3):652-61. doi: 10.3109/10428194.2013.807927. Epub 2013 Jul 1.

PMID:
23721511
46.

Multiple myeloma mimicking metastatic pancreas cancer.

Sher T, Bhat S, Jitawatanarat P, Desai N, Qiu J, Ma WW.

J Clin Oncol. 2013 Jun 20;31(18):e297-9. doi: 10.1200/JCO.2012.44.8845. Epub 2013 May 13. No abstract available.

PMID:
23669220
47.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic.

Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019. Erratum in: Mayo Clin Proc. 2013 Jul;88(7):777. Stewart, Keith [corrected to Stewart, A Keith].

PMID:
23541011
48.

The rate of epinephrine administration associated with allergy skin testing in a suburban allergy practice from 1997 to 2010.

Swender DA, Chernin LR, Mitchell C, Sher T, Hostoffer R, Tcheurekdjian H.

Allergy Rhinol (Providence). 2012 Fall;3(2):e55-60. doi: 10.2500/ar.2012.3.0034. Epub 2012 Dec 12.

49.

Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.

Sher T, Hayman SR, Gertz MA.

Clin Adv Hematol Oncol. 2012 Oct;10(10):644-51. Erratum in: Clin Adv Hematol Oncol. 2012 Nov;10(11):766.

PMID:
23187770
50.

Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.

Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2013 Feb;54(2):387-96. doi: 10.3109/10428194.2012.713481. Epub 2012 Aug 27.

Supplemental Content

Support Center